This study points to novel functional npcRNA candidates potentially involved in various regulatory roles including the pathogenicity of S. typhi.”
“Late embryogenesis abundant (LEA) group 4 (LEA4) proteins play an important role in the water stress tolerance of plants. Although they have been hypothesized to stabilize macromolecules in stressed cells,

the protective AG-881 purchase functions and mechanisms of LEA4 proteins are still not clear. In this study, the metal binding properties of two related soybean LEA4 proteins, GmPM1 and GmPM9, were tested using immobilized metal ion affinity chromatography (IMAC). The metal ions Fe(3+), Ni(2+), Cu(2+) and Zn(2+) were observed to bind these two proteins, while Ca(2+), Mg(2+) or Mn(2+) did not. Results from isothermal titration calorimetry (ITC) indicated that the binding affinity of GmPM1 for Fe(3+) was stronger than that of GmPM9. Hydroxyl radicals generated by the Fe(3+)/H(2)O(2) system were scavenged by both GmPM1 and GmPM9 in the absence or the presence of high ionic conditions (100 mM NaCl), although the scavenging activity of GmPM1 was significantly greater than that of GmPM9. These CX-6258 price results suggest that GmPM1 and GmPM9 are metal-binding proteins which may function in reducing oxidative damage induced by abiotic stress in plants.”
“PURPOSE: To evaluate the technical feasibility, acute and late genitourinary (GU) toxicity, and gastrointestinal toxicity after high-dose-rate (HDR) brachytherapy as monotherapy

in one fraction with transperineal hyaluronic acid injection into the perirectal fat to displace the rectal wall away from the radiation sources to decrease rectal toxicity.\n\nMETHODS AND MATERIALS: Between April 2008 and January 2010,40 consecutive patients were treated with favorable clinically localized prostate cancer; the median followup was 19 months (range, 8-32). No patients received external beam radiation,

and 35% received hormone therapy before brachytherapy. All patients received one implant and one fraction of HDR. Fraction dose was 19 Gy. Toxicity was reported according to the Common Toxicity Criteria for Adverse Event, Version 4.0.\n\nRESULTS: All patients LY2603618 ic50 tolerated the implantation procedure very well with minimal discomfort. No intraoperative or perioperative complications occurred. Acute toxicity Grade 2 or more was not observed in any patients. No chronic toxicity has been observed after treatment. Logistic regression showed that the late Grade 1 GU toxicity was associated with D-90 (p = 0.050). The 32-month actuarial biochemical control was 100% and 88%, respectively (p = 0.06) for low- and intermediate-risk groups.\n\nCONCLUSIONS: This is the first published report of the use of HDR brachytherapy as monotherapy in one fraction for patients with favorable-risk prostate cancer. This protocol is feasible and very well tolerated with low GU morbidity, no gastrointestinal toxicity, and the same level of low-dose-rate biochemical control at 32 months.